Analysis of antiasthmatic drugs for inhalation in the pharmaceutical market of Ukraine and dynamics of their consumption

Keywords: antiasthmatic drugs, pharmaceutical market, ATC/DDD methodology, consumption of antiasthmatic drugs for inhalation use

Abstract

Bronchial asthma (BA) is a common disease, as today the world suffers from about 300 million people. The number of patients with severe and complicated forms of BA is growing every year due to untimely diagnosis of the disease and late appointment of basic therapy. Complications cause disability in patients and increase mortality.

The purpose of this work was to study the range and consumption in Ukraine of antiasthmatic drugs for inhalation (ADI), intended for the treatment of BA for the period 2018–2020.

The analysis of the range and volumes of consumption of ADI was carried out according to the system of research of the market of medicines «Pharmstandard» of the company «Morion». Consumption estimates were made using the ATC/DDD methodology. DDDs/1 000 inhabitants/day (DID, DDDs per 1 000 inhabitants per day) was used as a unit of measurement.

The results showed that in the pharmaceutical market of Ukraine during 2018–2020 used 61–64 trade names (TN) ADI, of which 11–13 TN were domestically produced and 50–51 TN – foreign manufacturers. Retail prices for ADI during 2018–2020 varied widely and increased slightly each year, due to economic instability in the pharmaceutical market of Ukraine. It was found that the consumption of ADI in the period 2018–2019 increased slightly by 1.03 times – from 7.00 DID in 2018 to 7.24 DID in 2019. In 2020, the consumption of this group of drugs decreased 1.1 times – to 6.60 DID. The undisputed leader in consumption in Ukraine was salbutamol (3.53–3.56 DID), which is probably due to the clinical efficacy and sufficient safety of the drug, greater availability of salbutamol for the population due to the wide range of generic drugs in Ukraine. market and the state program «Affordable Medicines». The second place was taken by the combination of fenoterol + ipratropium bromide (0.81–0.85 DID), which is used in adults and children for the immediate treatment of sudden attacks of bronchospasm in BA. The third place in terms of consumption in Ukraine was occupied by the combination of salmeterol + fluticasone (0.52–0.54 DID), which is mainly prescribed to patients with moderate and severe asthma.

References

Feshchenko Yu. I. Aktualni problemy suchasnoi pulmonolohii // Ukr. pulmonolohichnyi zhurn. − 2018. − № 3. − S. 9‒15. ‒ URL: http://www.ifp.kiev.ua/doc/journals/upj/18_dop2/9.pdf

Feshhenko Yu. I. Novi pidxody pokrashhennya likuvannya bronxialnoyi astmy u svitovij praktyci // Asthma and Allergy. − 2019. − № 4. − S. 57‒58.

Corlateanu A., Stratan Iu., Covantev S. et al. Asthma and stroke: a narrative review // BMC. – 2021. – V. 7, N 3. https://doi.org/10.1186/s40733-021-00069-x

D’Amato G., Vitale C., Molino A. et al. Asthma-related deaths // BMC. – 2016. − V. 11, N 37. https://doi.org/10.1186/s40248-016-0073-0

Nurmagambetov T., Kuwahara R., Garbe P. The Economic Burden of Asthma in the United States, 2008–2013 // Ann. Am. Thorac Soc. – 2018. − V. 715, N 3. – Р. 348–356. https://doi.org/10.1513/AnnalsATS.201703-259OC

Chloe I. B., Preux L., Sheikh A., Quint J. K. Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study // Plos Medicines. – 2020. – N 7. https://doi.org/10.1371/journal.pmed.1003145

Easing the economic burden of Asthma. The impact of a universal asthma self-management programme. − 2019. ‒ URL: https://www.asthma.ie/sites/default/files/files/document_bank/2019/Jun/ASI%20-%20Easing%20the%20Economic%20Burden%20of%20Asthma%20Report.pdf

Mostovoi Yu. M., Demchuk A. V., Konstantynovych T. V. Bronkhialna astma – realna klinichna praktyka ta suchasni pidkhody do likuvannia //Astma ta alerhiia. − 2019. − № 4. − S. 70–72. ‒ URL: http://www.irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe

Feshchenko Yu. I. Bronkhialna astma. Khronichne obstruktyvne zakhvoriuvannia lehen v svitli suchasnykh rekomendatsii GINA (2017), SIGN 153 (2016), GOLD (2017), NICE (2010): praktykum likaria. − Kyiv: «Doktor-Media-Hrup», 2018. − 220 s.

Biset N., Kestens W., Detemmerman D. et al. Analysis of the Consumption of Drugs Prescribed for the Treatment of Asthma in Belgian Children // Int. J. Environ. Res. Public Health. – 2022. – V. 19, N 548. https://doi.org/10.3390/ijerph19010548

Mishchenko O. Ya., Khalieieva O. L. Rezultaty analizu asortymentu ta deiakykh farmakoekonomichnykh pokaznykiv inhaliatsiinykh bronkholitychnykh preparativ v Ukraini / Farmakoekonomika v Ukraini: stan ta perspektyvy rozvytku: mat. XII nauk.-prakt. internet-konf., m. Kharkiv, 22 travnia 2020 r. – S. 115.

Kostiuk I. A. Analiz dynamiky asortymentu likarskykh zasobiv dlia farmakoterapii bronkhialnoi astmy u prohrami «Dostupni liky» // Farmats. zhurn. – 2019. – T. 64, № 5. – S. 12‒20. https://doi.org/10.32352/0367-3057.5.19.02

Systema doslidzhennya rynku likarskyx zasobiv «Farmstandart» kompaniyi «Morion». ‒ URL: http://www.pharmstandart.com.ua

OECD, Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris. – 2019. – 211 p. https://doi.org/10.1787/4dd50c09-en

Published
2022-04-25
How to Cite
Tkachova, O. V., & Butko, Y. O. (2022). Analysis of antiasthmatic drugs for inhalation in the pharmaceutical market of Ukraine and dynamics of their consumption. Farmatsevtychnyi Zhurnal, (2), 15-24. https://doi.org/10.32352/0367-3057.2.22.02
Section
Management of pharmacy